Other single compounds

(Unterschied zwischen Versionen)

Wechseln zu: Navigation, Suche

Version vom 8. Juli 2020, 09:22 Uhr

Thymosin

32442287 2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.

Thymoquinone
32588453 2020. Covid-19 and Thymoquinone: Connecting the Dots.

G-CSF, GM-CSF
32419212 2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?
32576980 2020. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.
32559419 2020. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.

hzVSF‐v13 Humanized virus suppressing factor‐variant 13 (hzVSF‐v13) is a monoclonal IgG4 against vimentin, which is expressed on the surface of virus‐infected cells.
32458425 2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.

Omalizumab
32510814 2020. Omalizumab and COVID19 Treatment: Could It Help? Anti-IgE mab, -IL6,-TNF,-IL1,-NFKB

Almitrine
32505756 2020. Almitrine as a non-ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients.
32505755 2020. Effect of almitrine bismesylate and inhaled nitric oxide on oxygenation in COVID-19 acute respiratory distress syndrome.
32512007 2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.

H2S
32515982 2020. H2S as a potential defence against COVID-19?

Oleoylethanolamide
32327293 ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19

Lauric acid nat. compd.

call for trial

Dipyridamole retarget
32318327 ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

CGRP calcitonin gene related peptide antagonists
32386433 2020. Could CGRP Antagonists Be Helpful in the Fight Against COVID-19?

Various Leads

32251767 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)

BRD4 polycomb
32495654 2020. Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.

Glycyrrhizin
32335281 ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19

32077621 2020. Glycyrrhizic-Acid-Based Carbon Dots with High Antiviral Activity by Multisite Inhibition Mechanisms

32458502 2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.
32592716 2020. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?

Ipecac
32245264 2020. Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses

cathepsin L
32470470 2020. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.

Camostat mesilate serine proteinase inh
32347443 ä. Camostat mesilate therapy for COVID-19
32489508 2020. Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?

Nafamostat mesilate serine proteinase inh
32312781 2020. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
32302456 2020. Potential of heparin and nafamostat combination therapy for COVID-19
32470602 2020. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.

32532094 2020. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.

Sodium pyruvate
32378817 2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients

alpha1 adrenergic antagonists
32352407 2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists
32237190 ä. What does androgenetic alopecia have to do with COVID?19? An insight into a potential new therapy

Ciclesonide
32362440 ä. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases

Melatonin
32217117 2020. COVID-19: Melatonin as a potential adjuvant treatment
32360622 2020. Comment on Melatonin as a potential adjuvant treatment for COVID-19
32334009 2020. Correspondence COVID-19: Melatonin as a potential adjuvant treatment
32347747 2020. Can melatonin reduce the severity of COVID-19 pandemic?
32314850 2020. Melatonin: Roles in influenza, Covid?19, and other viral infections
32422305 2020. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.

cannabinoids
32360437 ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?
32273254 2020. Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic
32519753 2020. The potential of cannabidiol in the COVID-19 pandemic: a hypothesis letter.
32380847 2020. Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence
32467020 2020. A...: Cannabidiol as a potential anti-inflammatory treatment? .
32471272 2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?
32576053 2020. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients.

Oxytocin
32344303 ä. Oxytocin as a potential defence against Covid-19?

Botox
32352081 ä. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19

Endothelin antagonists
32361169 2020. Why not consider an endothelin receptor antagonist against SARS?CoV?2?
32360293 2020. Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?

Rho kinase inhibitors
32283223 2020. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)
32430287 2020. Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.

Saikosaponins
32353743 2020. Purposing Saikosaponins for the treatment of COVID-19
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets

Clozapine
32475694 2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.

Olanzapine
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)

ADAM17 as target
32291449 ä. ADAM17 inhibition may exert a protective effect on COVID-19

Dextrometorphan

dextrometorphan (antitussive compd)

Nitazoxanide
32405422 2020. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.
32360581 ä. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management

tPA

32312290 2020. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis

31856018 2020. Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?

32427774 2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.

32427773 2020. Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.

Plasminogen
32275753 ä. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19

Hesperidin
32531538 2020. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?

Diacerein
32534337 2020. Diacerein: A potential multi-target therapeutic drug for COVID-19.

CD147
32307653 ä. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

Bee venom
32360140 ä. Bee venom and SARS-CoV-2

Spironolactone
32297520 2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?

Luteolin
32339387 2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin

Pannexin1 channels
32519892 2020. Consideration of Pannexin 1 channels in COVID-19 pathology and treatment.

NAD+
32534944 2020. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.

Celastrol
32347602 2020. Should we try the antiinflammatory natural product, celastrol, for COVID-19?

1
32352871 2020. A Radiation Mitigator as a Potential Treatment for COVID-19

Ozone
C7203037 ä. (Vitamin-C; Ozone)Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19?
32462858 2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.

stimulating the Platelets

32315397 2020. Promoting platelets is a therapeutic option to combat severe viral infection of the lung

Thrombomodulin
23607598 2013. (x)Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome

Chlorpromazine
32387014 ä. Repositionnement de la chlorpromazine ... psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments

paper

Lipids
32345532 2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.

32429572 2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.
32408699 2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.
32457038 2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.

Resolvins
32416413 2020. Covid-19 management with inflammation resolving mediators? Perspectives and potential

beta adrenergic antagonists
32388480 2020. Can beta-adrenergic blockers be used in the treatment of COVID-19?

mabs
32534226 2020. Monoclonal antibody as a potential anti-COVID-19.
32514101 2020. First antibody against COVID-19 spike protein enters phase I.
32422645 2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
32512271 2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.

tlr's
32391920 2020. Consider TLR5 for new therapeutic development against COVID-19.

lactoferrin
32529963 2020. Can lactoferrin boost human immunity against COVID-19?

Famotidine
32446698 2020. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
32499303 2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.

Ursodeoxycholic acid
32505909 2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.

Diethylcarbamazine anti-filarial
32492560 2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?

Nitrofurazoxide

32504751 2020. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.

Parthenolide
32472655 2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.

Proteasome inh
32443911 2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.

Lidocaine
32505070 2020. Nebulized Lidocaine in COVID-19, An Hypothesis.

Escin
32441805 2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin. Methioninase
32503816 2020. Oral Methioninase for Covid-19 Methionine-restriction Therapy.

Thalidomide
C7186126 ä. Proposed use of thalidomide for the cytokine storm of COVID-19
32508009 2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.

Valproic acid
32498007 2020. Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid.

Pentoxyfylline
32449676 2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.
32473070 2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
32485316 2020. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.

PARP inh
32441764 2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?

P selectin block
32464083 2020. P-selectin blockade in COVID-19-related ARDS.

CD14
32574958 2020. Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.

Proteasome
32442437 2020. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Endoplasmic reticulum stress
32454157 2020. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.
32561291 2020. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?

Lysosomes, Autophagy, Membranes
32522674 2020. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.
32522067 2020. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
32521191 2020. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
32425923 2020. Could the Inhibition of Endo-Lysosomal Two-Pore Channels (TPCs) by the Natural Flavonoid Naringenin Represent an Option to Fight SARS-CoV-2 Infection?
32449802 2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?

Salinomycin
32516655 2020. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.

Arteminisin
32405226 2020. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.

LMWF5A
32431755 2020. The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.

Quarternary ammonium compounds
32451736 2020. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19.

Kv1.3 chanels
32581194 2020. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?

Exportin-1
32569833 2020. Exportin 1 inhibition as antiviral therapy.

Aminosalicylates
32553757 2020. Aminosalicylates and COVID-19: Facts or Coincidences?

Quinoxalines
32560203 2020. Quinoxaline Derivatives as Antiviral Agents: A Systematic Review.

Pirfenidone
32575019 2020. Pirfenidone: A novel hypothetical treatment for COVID-19.

Adenosinergic signaling
32590324 2020. Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis.

Galectin-3
32587806 2020. A potential role for Galectin-3 inhibitors in the treatment of COVID-19.

Auranofin
32547693 2020. A Role for Metal-Based Drugs in Fighting COVID-19 Infection? The Case of Auranofin.

microbiome 2x

32579014 2020. Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19.

32552848 2020. Compassionate use of others' immunity - understanding gut microbiome in Covid-19.

@@ Zeile 3: / Zeile 3: @@
 {{ttp|p=32442287|t=2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.|pdf=|usr=007}}
-'''G-CSF'''
+'''Thymoquinone'''
+{{tp|p=32588453|t=2020. Covid-19 and Thymoquinone: Connecting the Dots.|pdf=|usr=010}}
+'''G-CSF, GM-CSF'''
 {{tp|p=32419212|t=2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?|pdf=|usr=007}}
+{{tp|p=32576980|t=2020. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.|pdf=|usr=010}}
+{{tp|p=32559419|t=2020. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.|pdf=|usr=010}}
 '''hzVSF‐v13'''
@@ Zeile 59: / Zeile 65: @@
 {{ttp|p=32077621|t=2020. Glycyrrhizic-Acid-Based Carbon Dots with High Antiviral Activity by Multisite Inhibition Mechanisms |pdf=|usr=}}
 {{tp|p=32458502|t=2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.|pdf=|usr=007}}
+{{tp|p=32592716|t=2020. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?|pdf=|usr=010}}
 '''Ipecac'''
 {{tp|p=32245264|t=2020. Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses |pdf=|usr=}}
+'''cathepsin L'''
+{{tp|p=32470470|t=2020. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.|pdf=|usr=009}}
 '''Camostat mesilate''' serine proteinase inh
@@ Zeile 71: / Zeile 82: @@
 {{tp|p=32302456|t=2020. Potential of heparin and nafamostat combination therapy for COVID-19 |pdf=|usr=}}
 {{tp|p=32470602|t=2020. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.|pdf=|usr=008}}
+{{ttp|p=32532094|t=2020. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.|pdf=|usr=009}}
 '''Sodium pyruvate'''
@@ Zeile 98: / Zeile 109: @@
 {{tp|p=32380847|t=2020. Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence{{tp|p=32467020|t=2020. A...: Cannabidiol as a potential anti-inflammatory treatment?|pdf=|usr=008}}.|pdf=|usr=008}}
 {{tp|p=32471272|t=2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?|pdf=|usr=007}}
+{{tp|p=32576053|t=2020. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients.|pdf=|usr=010}}
 '''Oxytocin'''
@@ Zeile 116: / Zeile 130: @@
 '''Rho kinase inhibitors'''
 {{tp|p=32283223|t=2020. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) |pdf=|usr=}}
+{{tp|p=32430287|t=2020. Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.|pdf=|usr=009}}
 '''Saikosaponins'''
@@ Zeile 281: / Zeile 295: @@
 '''P selectin block'''
 {{tp|p=32464083|t=2020. P-selectin blockade in COVID-19-related ARDS.|pdf=|usr=007}}
+'''CD14'''
+{{tp|p=32574958|t=2020. Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.|pdf=|usr=010}}
+'''Proteasome'''
+{{tp|p=32442437|t=2020. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.|pdf=|usr=009}}
+'''Endoplasmic reticulum stress'''
+{{tp|p=32454157|t=2020. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.|pdf=|usr=009}}
+{{tp|p=32561291|t=2020. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?|pdf=|usr=010}}
 '''Lysosomes, Autophagy, Membranes'''
@@ Zeile 292: / Zeile 317: @@
 {{tp|p=32516655|t=2020. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.|pdf=|usr=009}}
+'''Arteminisin'''
+{{tp|p=32405226|t=2020. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.|pdf=|usr=009}}
-'''microbiome''' 2x
+'''LMWF5A'''
-{{tp|p=32495940|t=2020. Probiotics and COVID-19: is there any link?|pdf=|usr=007}}
+{{tp|p=32431755|t=2020. The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.|pdf=|usr=009}}
-{{tp|p=32475223|t=2020. Antiviral effects of probiotic metabolites on COVID-19.|pdf=|usr=007}}
+'''Quarternary ammonium compounds'''
+{{tp|p=32451736|t=2020. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19.|pdf=|usr=009}}
+'''Kv1.3 chanels'''
+{{tp|p=32581194|t=2020. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?|pdf=|usr=010}}
+'''Exportin-1'''
+{{tp|p=32569833|t=2020. Exportin 1 inhibition as antiviral therapy.|pdf=|usr=010}}
+'''Aminosalicylates'''
+{{tp|p=32553757|t=2020. Aminosalicylates and COVID-19: Facts or Coincidences?|pdf=|usr=010}}
+'''Quinoxalines'''
+{{tp|p=32560203|t=2020. Quinoxaline Derivatives as Antiviral Agents: A Systematic Review.|pdf=|usr=010}}
+'''Pirfenidone'''
+{{tp|p=32575019|t=2020. Pirfenidone: A novel hypothetical treatment for COVID-19.|pdf=|usr=010}}
+'''Adenosinergic signaling'''
+{{tp|p=32590324|t=2020. Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis.|pdf=|usr=010}}
+'''Galectin-3'''
+{{tp|p=32587806|t=2020. A potential role for Galectin-3 inhibitors in the treatment of COVID-19.|pdf=|usr=010}}
+'''Auranofin'''
+{{tp|p=32547693|t=2020. A Role for Metal-Based Drugs in Fighting COVID-19 Infection? The Case of Auranofin.|pdf=|usr=011}}
+'''microbiome''' 2x
+{{ttp|p=32579014|t=2020. Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19.|pdf=|usr=010}}
+{{tp|p=32552848|t=2020. Compassionate use of others' immunity - understanding gut microbiome in Covid-19.|pdf=|usr=010}}

Other single compounds

Version vom 8. Juli 2020, 09:22 Uhr

Meine Werkzeuge

Namensräume

Varianten

Ansichten

Aktionen

Suche

Navigation

Werkzeuge